Equities analysts expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to announce sales of $290,000.00 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Alpine Immune Sciences’ earnings. The highest sales estimate is $320,000.00 and the lowest is $250,000.00. Alpine Immune Sciences reported sales of $320,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 9.4%. The company is scheduled to announce its next quarterly earnings results on Monday, May 13th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year sales of $1.13 million for the current fiscal year, with estimates ranging from $1.00 million to $1.26 million. For the next financial year, analysts forecast that the business will post sales of $1.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its earnings results on Monday, March 18th. The biotechnology company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80).

A number of analysts have recently weighed in on the stock. Oppenheimer set a $13.00 price target on shares of Alpine Immune Sciences and gave the company a “buy” rating in a report on Tuesday, March 19th. ValuEngine upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a report on Tuesday, March 26th. Finally, restated a “buy” rating and issued a $13.00 price target on shares of Alpine Immune Sciences in a report on Tuesday, February 12th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Alpine Immune Sciences presently has a consensus rating of “Buy” and a consensus price target of $12.07.

Shares of NASDAQ:ALPN traded down $0.45 during trading on Tuesday, reaching $6.75. The stock had a trading volume of 23,570 shares, compared to its average volume of 15,783. Alpine Immune Sciences has a one year low of $3.66 and a one year high of $10.57. The stock has a market capitalization of $99.75 million, a P/E ratio of -2.57 and a beta of 2.13. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.59 and a current ratio of 6.59.

In other news, major shareholder Tiger Management L.L.C. sold 25,000 shares of the firm’s stock in a transaction dated Friday, February 8th. The shares were sold at an average price of $5.85, for a total value of $146,250.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 69.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in ALPN. Hikari Power Ltd acquired a new stake in Alpine Immune Sciences in the 4th quarter worth approximately $453,000. Victory Capital Management Inc. boosted its stake in Alpine Immune Sciences by 109.0% in the 4th quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 70,980 shares in the last quarter. Vanguard Group Inc. boosted its stake in Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares in the last quarter. Finally, Vanguard Group Inc boosted its stake in Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares in the last quarter. Institutional investors own 53.79% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

See Also: Why Invest in Dividend Achievers?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.